SUMMARY Antisecretory effect of single oral therapeutic doses of pirenzepine (25 mg and 50 mg) and cimetidine (200 mg and 400 mg) was studied in 12 patients with duodenal ulcer. Gastric secretion was studied in basal condition and after stimulation with pentagastrin. Basal, maximum and peak acid output, basal and maximum acidity, and basal and maximum volume were calculated after computerised correction for pyloric loss and duodenal reflux. Both drugs showed dose-related inhibition of all facets of gastric secretion. Cimetidine (200 mg) had a greater inhibitory effect on gastric basal secretion, but a similar effect on pentagastrin stimulated secretion as with pirenzepine (50 mg). Cimetidine (400 mg) showed about twice the inhibitory activity of pirenzepine (50 mg) both on basal and stimulated secretion.
The inhibitory effect of pirenzepine on gastric secretion in man has been shown both in basal conditions and on secretion stimulated by pentagastrin.14 As almost all previous studies on pirenzepine were performed with uncorrected data on gastric secretion the extent of the inhibition reported by different authors varies from 14%2 to 97%' for basal output and from 22 %5 to 56%' for the output stimulated by pentagastrin. The difference in these results is attributed to the difference in: (1) dosage used; (2) routes of administration; (3) techniques of study of the gastric secretion; and (4) the sample on which the study has been carried out.
In order to obtain univocal data on the inhibitory capacity of pirenzepine on gastric secretion, we studied the effects of single doses of pirenzepine on basal and pentagastrin stimulated gastric secretion, calculated with computerised correction for pyloric loss and duodenal reflux, and compared these with single doses of cimetidine, the histamine H2 receptor antagonist already used in other studies as the substance for reference purposes.6 7 At the beginning of the second and third test, a check was made to confirm that there was no residue of drug in the gastric juice. After the first basal 30 minutes, pentagastrin (Gastrodiagnost, Merck) 6 ,ug/kg/h was infused (Perfusor V, Braun) for a period of 90 minutes. Volume, pH, and titratable acidity (to pH 7) of each sample were measured (autotitrator Radiometer).
Pyloric loss was estimated by the colorimetric method using an intragastric infusion of phenol red while duodenal reflux was measured on the basis of sodium concentration in the gastric aspirate according to Hobsley's formula.
Basal, maximum and peak acid output, basal and maximum acidity, basal and maximum volume were calculated with computerised correction for pyloric loss and duodenal reflux.10 ' 
TREATMENT
The single doses compared with each other were 25 and 50 mg pirenzepine and 200 and 400 mg cimetidine, administered in the form of powder contained in identical wafers.
EXPERIMENTAL DESIGN
The study was designed as a double-blind balanced incomplete block cross-over trial with randomised sequences. Each patient was subjected, in random order, to two of four possible treatments at intervals of at least 48 hours one from the other.
The characteristics of the experimental design were: K=4 treatments -that is, two doses of pirenzepine and two of cimetidine; n=6 replications, each dose being replicated in six patients; b=12 blocks -that is, 12 patients; u=2 block units -that is, treatments per patient; X=2 pair replications; with an efficiency (E) of 67% with respect to the complete randomised blocks design. This evaluation was made possible because of the experimental design previously used by us in a similar study,7 which allows the reduction of gastric function tests undergone by the same subject, from five to three, with an experimental efficiency of almost 70%.
Our results confirm the inhibitory effect of pirenzepine on all facets of gastric secretion, related to the dose. As far as stimulated secretion (MAO, PAO, maximum volume, and acidity) was concerned, the effect of pirenzepine at its highest dosage (50 mg) was similar to that of cimetidine at its lowest dosage (200 mg). Therefore if it is necessary to increase the dosage of these drugs in order to obtain a higher inhibition, which could be therapeutically more efficacious, this is possible with cimetidine, used successfully at a dose of 400 mg bid,13 whereas pirenzepine at higher dosage induces unwanted muscarine effects.14 15 In fact three of our patients presented such side effects after a dose of 50 mg.
In this trial we did not study the combination of the two drugs as used by Londong et al. 16 After a single intravenous bolus injection of cimetidine plus pirenzepine, at a ratio of one to 10, they obtained an almost complete inhibition of acid secretion but with unpleasant side effects.
On the basis of our results we think that in order to obtain a significant reducLion of gastric acid secretion, with no side effects, cimetidine should be the first choice owing to its superior efficacy and absence of remarkable side effects. 
